E-3810 clinical trials
Also written Lucitanib, AL3810 and E-3810.
How each study uses E-3810 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 3
Haihe Biopharma Co., Ltd. (4) · Eisai Co., Ltd. (3) · Clovis Oncology, Inc. (3) · Institut de Recherches Internationales Servier (2) · Eisai Inc. (1) · Teresa Helsten, MD (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses E-3810 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After ChemotherapyCompletedPhase 2Haihe Biopharma Co., Ltd.NCT07824505Written as lucitanib 15 mg QD
- A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast CancerCompletedPhase 2Institut de Recherches Internationales ServierNCT02053636Written as lucitanib
- Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid TumorsCompletedPhase 1/2Institut de Recherches Internationales ServierNCT01283945Written as Lucitanib
- A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorSuspendedPhase 1/2Clovis Oncology, Inc.NCT04042116Written as Lucitanib
- A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerTerminatedPhase 2Clovis Oncology, Inc.NCT02202746Written as Lucitanib
- This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in PatientsStatus unknownPhase 2/3Haihe Biopharma Co., Ltd.NCT04254471Written as AL3810
- A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic AlterationsTerminatedPhase 2Clovis Oncology, Inc.NCT02109016Written as Lucitanib
- Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway AberrationsWithdrawnPhase 2Teresa Helsten, MDNCT02747797Written as Lucitanib
- Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownPhase 1Haihe Biopharma Co., Ltd.NCT03260179Written as AL3810
- Study of the AL3810 in the Treatment of Advanced Solid TumorCompletedPhase 1Haihe Biopharma Co., Ltd.NCT03117101Written as Lucitanib
- Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)CompletedPhase 2/3Eisai Co., Ltd.NCT01397448Written as E3810
- A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg TabletsCompletedPhase 1Eisai Inc.NCT01153659Written as E3810
- Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux EsophagitisCompletedPhase 2/3Eisai Co., Ltd.NCT00770913Written as E3810
- A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux DiseaseCompletedPhase 3Eisai Co., Ltd.NCT00165646Written as E3810
Given beside what is tested · 2 — E-3810 is usual care or a partner of the new treatment
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)TerminatedPhase 1/2pharmaand GmbHNCT03992131Written as Lucitanib
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnPhase 1/2Bristol-Myers SquibbNCT04151563Written as lucitanib